Wall Street analysts expect Endologix, Inc. (NASDAQ:ELGX) to announce sales of $35.26 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Endologix’s earnings. The lowest sales estimate is $35.00 million and the highest is $35.58 million. Endologix posted sales of $34.76 million in the same quarter last year, which suggests a positive year-over-year growth rate of 1.4%. The business is scheduled to report its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Endologix will report full year sales of $142.70 million for the current financial year, with estimates ranging from $142.10 million to $143.85 million. For the next year, analysts forecast that the company will report sales of $150.91 million, with estimates ranging from $150.00 million to $152.07 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Endologix.
Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%. The company had revenue of $36.24 million during the quarter, compared to the consensus estimate of $36.09 million.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Endologix during the second quarter worth $91,000. M&T Bank Corp acquired a new position in shares of Endologix during the second quarter worth $102,000. Zacks Investment Management acquired a new position in shares of Endologix during the second quarter worth $108,000. HighTower Advisors LLC acquired a new position in shares of Endologix during the second quarter worth $145,000. Finally, Walleye Trading LLC acquired a new position in shares of Endologix during the second quarter worth $158,000. 48.44% of the stock is currently owned by institutional investors and hedge funds.
ELGX traded down $0.01 during trading on Friday, hitting $6.10. 242,300 shares of the company’s stock were exchanged, compared to its average volume of 261,542. The company has a current ratio of 2.53, a quick ratio of 0.90 and a debt-to-equity ratio of 2.45. Endologix has a 1 year low of $5.20 and a 1 year high of $26.50. The stock has a 50 day moving average price of $6.75 and a 200 day moving average price of $5.69. The firm has a market cap of $112.90 million, a P/E ratio of -0.85 and a beta of 0.37.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Featured Article: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.